| Business Summary | | Coceptus,
Inc.
develops,
manufactures
and
markets
a
proprietary
non-surgical
permanent
birth
control
device
for
women.
Its
Selective
Tubal
Occlusion
Procedure
(STOP)
delivers
a
flexible
micro-coil
into
a
woman's
fallopian
tubes,
and
is
designed
to
provide
permanent
birth
control
by
causing
a
tissue
in-growth
that
blocks
the
fallopian
tubes.
STOP
is
typically
performed
as
an
outpatient
procedure,
and
is
intended
to
be
a
less
invasive,
safer
and
less
costly
alternative
to
tubal
ligation.
Tubal
ligation
involves
abdominal
incisions,
general
anesthesia,
three
to
four
days
of
recovery
time
and
the
risks
associated
with
a
surgical
procedure.
The
STOP
procedure
is
a
minimally
invasive,
approximately
20-minute
outpatient
procedure
that
is
usually
performed
with
only
a
local
anesthetic.
No
hospital
stay
is
required,
and
patients
are
expected
to
resume
normal
activities
within
hours
of
the
procedure. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Conceptus,
Inc.
designs,
develops
and
markets
minimally
invasive
devices
for
reproductive
medical
applications.
For
the
six
months
ended
6/30/01,
revenues
totaled
$163
thousand,
up
from
$0
thousand.
Net
loss
rose
79%
to
$8.3
million.
Revenues
reflect
the
first
Essure
pbc
sales
in
Australia.
Earnings
were
offset
by
increased
marketing
expenses
to
support
the
commercial
launch
of
Essure
pbc
and
higher
administrative
costs
for
the
growth
of
manufacturing
activities. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Kathryn Tunstall, 50 Chairman | $163K | Steve Bacich, 39 Pres,
CEO, Director | 242K | Glen Furuta, 39 CFO,
VP of Fin. and Admin. | -- | Cynthia Domecus, 41 Sr.
VP of Clinical Research, Regulatory Affairs | 243K | William Dippel VP-Operations | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|